Recent developments highlight the company's strategic shift and operational activities, including a name change to reflect expansion, acquisition of DeepSolar, launch of a pilot program, and a commercial collaboration agreement to accelerate solar analytics business.

• PainReform Ltd. gained $3.17 million from a warrant exercise, providing additional capital [N1].
• The company changed its corporate name to PRF Technologies Ltd. to reflect its business expansion beyond pharmaceuticals [N2].
• PainReform Ltd. launched a strategic pilot program with Econergy Renewable Energy Ltd. to optimize solar energy production using its DeepSolar platform [N4].
• The company completed the acquisition of DeepSolar, expanding into the clean energy sector [N5].
• PainReform Ltd. acquired DeepSolar to expand into the solar analytics market [N6].

The company has diversified its business model by acquiring DeepSolar, positioning itself in the growing clean energy analytics market. Strategic collaborations, such as the agreement with Blade Ranger to accelerate commercial engagements, demonstrate active efforts to commercialize its new technology. The proprietary pharmaceutical technology also addresses a critical healthcare need, potentially offering differentiated products in pain management.

The company reported a significant net loss and minimal revenue in the latest fiscal year, indicating challenges in achieving profitability. The transition from pharmaceuticals to clean energy introduces execution risks and potential dilution of focus. Limited liquidity and trading volume of its shares may contribute to stock price volatility. The company also faces risks from economic uncertainty and geopolitical instability, which could impact operations and investor sentiment.

The company's moat lies in its proprietary extended-release drug-delivery system for pain management, which addresses a significant medical need by potentially reducing opioid use. Additionally, its expansion into AI-driven solar analytics through the DeepSolar acquisition introduces a technology-driven competitive edge in the clean energy sector. However, the transition into a new industry and the early stage of commercial engagements may limit the immediate strength of its moat.

• Economic and Geopolitical Uncertainty: The company operates amid economic uncertainty and geopolitical instability, including the ongoing conflict between Russia and Ukraine, which may adversely affect its business and stock price [S1].
• Liquidity and Market Risks: Limited liquidity and trading volume of the company's shares may result in price volatility and difficulty for investors to liquidate positions [S1].
• Execution Risks in Business Expansion: The company's expansion into the clean energy sector through acquisition and new collaborations involves execution risks, including integration challenges and market acceptance [S1][N5][N6][S2].
• Financial Performance Risks: The company reported a net loss and minimal revenue, indicating ongoing challenges in achieving sustainable profitability [S1].
• Dependence on Management Estimates: Significant management judgment is involved in accounting for acquisitions and business combinations, which may affect reported financial results [S1].

• PAINREFORM LTD. is a specialty pharmaceutical company focused on reformulating established therapeutics using a proprietary extended-release drug-delivery system designed for extended post-surgical pain relief and reduced opioid use [S1].
• In March 2025, the company acquired DeepSolar, an AI-driven solar analytics technology business, marking an expansion into the clean energy sector [S1][N5][N6].
• On January 6, 2026, the company changed its name from PainReform Ltd. to PRF Technologies Ltd. to reflect its business expansion [S1][N2].
• The company is incorporated in Israel with principal executive offices in Tel Aviv [S1].
• PRF Technologies entered a commercial collaboration agreement with Blade Ranger Ltd. in March 2026 to accelerate large-scale commercial engagements for its DeepSolar solar energy business unit, with Blade Ranger receiving warrants as consideration for introducing business prospects [S2].
• The company reported fiscal year 2025 financials showing minimal revenue of $17,000 USD and a net loss of $5.022 million USD, with basic and diluted EPS of -7.47 USD per share [S1].
• As of December 31, 2025, the company held $3.125 million USD in cash and equivalents, with current assets of $4.351 million USD and current liabilities of $2.441 million USD, resulting in a current ratio of 1.78 and a cash ratio of 1.28 [S1].
• The company prepares its financial statements in accordance with U.S. GAAP and applies significant management judgment in accounting for acquisitions and business combinations [S1].
• The company faces risks related to economic uncertainty, geopolitical instability, limited liquidity and trading volume of its shares, and potential volatility in its stock price [S1].